药物警戒
医学
不利影响
不良事件报告系统
药理学
医学名词
梅德林
重症监护医学
政治学
法学
作者
Chenxin Chen,Xin Miao,Xiaojing Guo,Jinfang Xu,Jizhou Liang,Yi Zheng,Lijie Chi,Xiao Chen,Lianhui Wei,Hewei Zhang,Xiaofei Ye,Jia He
标识
DOI:10.1080/14740338.2023.2248888
摘要
Exportin 1 (XPO1) inhibitors are being developed as a new agent for anti-cancer therapies. This study aimed to broadly portray the adverse event (AE) profile of selinexor, an XPO1 inhibitor, in actual clinical practice.Disproportionality analyses were conducted by calculating the information component and reporting odds ratio in VigiBase over different reporting periods. All selinexor-related AEs were classified by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities.A total of 116,443 AEs were identified in 2,608 patients that received selinexor. Patients with cardiac disorders had a higher propensity for death. Thirteen SOCs and 125 PTs were identified as having a potential connection with selinexor. Notably, 29 suspected signals detected in our study were defined as significant AEs by the European Medicines Agency, including febrile neutropenia, pancytopenia, and acute kidney injury. Attention should be paid to these AEs, despite most toxicities being manageable and reversible.This study highlights a number of AEs associated with selinexor. Most toxicities are reversible but require careful management. The benefit of selinexor still outweighs the potential risks, indicating XPO1 inhibitors as promising agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI